BioMarin Pharma (BMRN) Misses Q4 EPS by 31c; offers guidance

BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.46, $0.31 worse than the analyst estimate of $0.77. Revenue for the quarter came in at $875 million versus the consensus estimate of $829.31 million.

GUIDANCE:

BioMarin Pharma sees FY2026 EPS of $4.95-$5.15, versus the consensus of $5.33. BioMarin Pharma sees FY2026 revenue of $3.325-3.425 billion, versus the consensus of $3.378 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.

You May Also Be Interested In

• McEwen Copper seeks $1.6b in equity financing for Los Azules - Bloomberg
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• 374Water Inc (SCWO) Misses Q2 EPS by 15c